Novel cytotoxic drugs: Old challenges, new solutions

Cancer Treatment Reviews

Volumn 34, Issue 1, 2008, Pages 81-91

  Ismael, Gustavo F V ^a,b   Rosa, Daniela Dornelles ^a,c   Mano, Max S ^a,d   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Hospital Amaral Carvalho   (Brazil)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Chemotherapy; Cytotoxic agents; Drug development; Novel drugs

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CREMOPHOR; CYTOTOXIC AGENT; DACARBAZINE; DAUNORUBICIN; DJ 927; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; FLUOROURACIL; IRINOTECAN; IXABEPILONE; LIPOSOME; MITOMYCIN; NANOPARTICLE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PACLITAXEL TOCOSOL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TAXOPREXIN; TEMOZOLOMIDE; TOCOSOL; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; XYTOTAX;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; KAPOSI SARCOMA; LETHARGY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SEPSIS; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT CANCER; VOMITING;

EID: 38649084461     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.08.001     Document Type: Review

References (95)

1. Green M.R. Targeting targeted therapy. N Engl J Med 350 21 (2004) 2191-2193
2. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 5698 (1979) 665-667
3. Hennenfent K.L., and Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol 17 5 (2006) 735-749
4. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8 5 (2002) 1038-1044
5. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12 4 (2006) 1317-1324
6. Nyman D.W., Campbell K.J., Hersh E., Long K., Richardson K., Trieu V., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23 31 (2005) 7785-7793
7. Damascelli B., Cantu G., Mattavelli F., Tamplenizza P., Bidoli P., Leo E., et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92 10 (2001) 2592-2602
8. Damascelli B., Patelli G.L., Lanocita R., Di Tolla G., Frigerio L.F., Marchiano A., et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol 181 1 (2003) 253-260
9. Ibrahim N.K., Samuels B., Page R., Doval D., Patel K.M., Rao S.C., et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23 25 (2005) 6019-6026
10. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 31 (2005) 7794-7803
11. Gradishar W., Krasnojon D., Cheporov S., et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Abstract 1032. J Clin Oncol 25 18S (2007) 1032
12. Greco A, et al. First-line therapy for advanced NSCLC. In: Proceedings of the chemotherapy foundation symposium XXIV; 2006.
13. Wolff A.C., Donehower R.C., Carducci M.K., Carducci M.A., Brahmer J.R., Zabelina Y., et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9 10 Pt 1 (2003) 3589-3597
14. Schacter L., Talbot D., Ellis P., Dunlop D., and Thatcher N. Safety and efficacy of DHA-paclitaxel (TXP) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22 14S (2004) [abstr. 7111]
15. Bellet R., Carducci M., Petrylak D., Kasimis B., Irwin D., Modiano M., et al. Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 22 14 suppl (2004) 4657
16. Johnston S.R.D., Houston S., Jones A., Evans T.R.J., and Schacter L. Efficacy of DHA-paclitaxel (TXP) for the second line treatment of breast cancer. Proc Am Soc Clin Oncol 22 (2003) [abstr. 65]
17. Jacobs A., Planting A., Ferry D., et al. Efficacy of DHA-paclitaxel in pancreatic cancer. Proc Am Soc Clin Oncol 21 (2003) [abstr. 1090]
18. Modiano M., Houston S., Savage P., et al. Efficacy of DHA-paclitaxel in malignant melanoma. Proc Am Soc Clin Oncol 21 (2003) [abstr. 2891]
19. Evans T.R., Hawkins R.W., Eatock M., et al. Efficacy of DHA-paclitaxel in adenocarcinoma of the esophagus or stomach. Proc Am Soc Clin Oncol 21 (2003) [abstr. 1154]
20. Singer J.W., Baker B., De Vries P., Kumar A., Shaffer S., Vawter E., et al. Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 519 (2003) 81-99
21. Bolton M., and Nemunaitis J. Phase I study of CT-2103/carboplatin in patients with solid tumors. Proc Am Soc Clin Oncol 21 (2003) [abstr. 646]
22. Kudelka A., Skubitz K.M., Kavanagh J.J., and Bolton M. Phase I study of CT-2103/cisplatin in patients with solid tumors. Proc Am Soc Clin Oncol 21 (2003) [abstr. 1841]
23. Sabbatini P., Aghajanian C., Dizon D., Anderson S., Dupont J., Brown J.V., et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22 22 (2004) 4523-4531
24. Richards D.A., Richards P., Bodkin D., Neubauer M.A., and Oldham F. Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study. Clin Lung Cancer 7 3 (2005) 215-220
25. O'Brien M., Bonomi P., Langer C., et al. Analysis of prognostic factors in chemo-nai{dotless}̈ve patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials. J Clin Oncol 24 18S (2006) [abstr. 7113]
26. Dipetrillo T.A., Chauhan B., Akerman P., et al. Paclitaxel poliglumex (PPX) and concurrent radiation for treatment of patients with esophageal or gastric cancer: a dose-ranging study. J Clin Oncol 23 16S (2005) [abstr. 4065]
27. Spigel S.C., Jones S.F., and Greco F.A. S-8184 vitamin E paclitaxel emulsion: preclinical and phase I data. Proc Am Soc Clin Oncol 20 (2002) [abstr. 406]
28. Bogdanova N., Lissianskaya A., and Gorelov A. Paclitaxel vitamin E emulsion: phase I/II study of weekly administration in patients with non-small cell lung cancer, transitional cell, ovarian, or colorectal cancer. Proc Am Soc Clin Oncol 21 (2003) [abstr. 988]
29. Gorelov A., Gorelov S., Karlov P., Golubeva O., and Stewart M. Paclitaxel injectable emulsion: phase 2a study of weekly administration in patients with metastatic or locally advanced unresectable or recurrent urothelial transitional cell cancer (TCC). J Clin Oncol (Meet Abstr.) 22 Suppl. 14 (2004) 4586
30. Bogdanova N., Karaseva N., and Ognerubov N. Paclitaxel injectable emulsion: phase 2a study of weekly administration in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 22 14S (2004) [abstr. 649]
31. Lissianskaya A., Gershanovich M., and Ognerubov N. Paclitaxel injectable emulsion: phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer. Proc Am Soc Clin Oncol 22 14S (2004) [abstr. 460]
32. Schuch G. EndoTAG-1. MediGene. Curr Opin Invest Drug 6 12 (2005) 1259-1265
33. Shionoya M., Jimbo T., Kitagawa M., Soga T., and Tohgo A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94 5 (2003) 459-466
34. Ono C., Takao A., and Atsumi R. Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys. Biol Pharm Bull 27 3 (2004) 345-351
35. Syed S.K., Beeram M., Takimoto C.H., et al. Phase I and pharmacokinetics of DJ-927, an oral taxane, in patients with advanced cancers. Proc Am Soc Clin Oncol 22 14S (2004) [abstr. 2028]
36. Moore M.R., Jones C., Harker G., et al. Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 24 18S (2006) [abstr. 3591]
37. Evans T., Dobrila R., Berardi R., et al. A phase II study of DJ-927 as second-line therapy in patients with advanced gastric cancer who have failed FU no taxane regimen. J Clin Oncol 24 18S (2006) [abstr. 198]
38. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57 7 (1999) 727-741
39. Buzdar A.U., Marcus C., Smith T.L., and Blumenschein G.R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55 12 (1985) 2761-2765
40. Law T.M., Mencel P., and Motzer R.J. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drug 12 4 (1994) 323-325
41. Harrison M., Tomlinson D., and Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13 4 (1995) 914-920
42. Gill P.S., Espina B.M., Muggia F., Cabriales S., Tulpule A., Esplin J.A., et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13 4 (1995) 996-1003
43. Money-Kyrle J.F., Bates F., Ready J., Gazzard B.G., Phillips R.H., and Boag F.C. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol (R Coll Radiol) 5 6 (1993) 367-371
44. Boiardi A., Pozzi A., Salmaggi A., Eoli M., Zucchetti M., and Silvani A. Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. Cancer Chemother Pharmacol 43 2 (1999) 178-179
45. Gordon A.N., Tonda M., Sun S., and Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 1 (2004) 1-8
46. Al-Batran S.E., Bischoff J., von Minckwitz G., Atmaca A., Kleeberg U., Meuthen I., et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Brit J Cancer 94 11 (2006) 1615-1620
47. Chia S., Clemons M., Martin L.A., Rodgers A., Gelmon K., Pond G.R., et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24 18 (2006) 2773-2778
48. Keller A.M., Mennel R.G., Georgoulias V.A., Nabholtz J.M., Erazo A., Lluch A., et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22 19 (2004) 3893-3901
49. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 3 (2004) 440-449
50. Abraham J., Agrawal M., Bakke S., Rutt A., Edgerly M., Balis F.M., et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21 9 (2003) 1866-1873
51. Gadgeel S.M., Wozniak A., Boinpally R.R., Wiegand R., Heilbrun L.K., Jain V., et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 11 17 (2005) 6233-6239
52. Low J.A., Wedam S.B., Lee J.J., Berman A.W., Brufsky A., Yang S.X., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23 12 (2005) 2726-2734
53. Thomas E., Tabernero J., Fornier M., Conte P., Fumoleau P., Lluch A., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25 (2007) 3399-3406
54. Roche H., Yelle L., Cognetti F., Mauriac L., Bunnell C., Sparano J., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25 (2007) 3415-3420
55. Denduluri N., Low J.A., Lee J.J., Berman A.W., Walshe J.M., Vatas U., et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25 (2007) 3421-3427
56. Hussain M., Tangen C.M., Lara Jr. P.N., Vaishampayan U.N., Petrylak D.P., Colevas A.D., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23 34 (2005) 8724-8729
57. Whitehead R.P., McCoy S., Rivkin S.E., Gross H.M., Conrad M.E., Doolittle G.C., et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drug 24 6 (2006) 515-520
58. Kowalski R.J., Giannakakou P., and Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272 4 (1997) 2534-2541
59. Rubin E.H., Rothermel J., Tesfaye F., Chen T., Hubert M., Ho Y.Y., et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23 36 (2005) 9120-9129
60. Forster M., Kaye S., Oza A., Sklenar I., Johri A., Cheung W., et al. A phase ib and pharmacokinetic trial of patupilone combined with Carboplatin in patients with advanced cancer. Clin Cancer Res 13 14 (2007) 4178-4184
61. Klar U, Buchmann B, Schwede W, et al. ZK-EPO, a novel synthetic epothilone B analog, significantly inhibits tumor growth in both non-resistant and resistant breast cancer models. In: Proc San Antonio Breast Cancer Symp; 2005 [abstr. 1072].
62. Buzdar A, Silverman P, Kaufman PA, et al. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. In: Proc San Antonio Breast Cancer Symp; 2005 [abstr. 1087].
63. Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4 7 (2005) 1086-1095
64. Blum J., Forero L., Heiskala M.K., et al. E7389, a novel anti-tubulin, in patients with refractory breast cancer. Proc Am Soc Clin Oncol 24 18S (2006) [abstr. 653]
65. Das A., Spira A., Iannotti N., et al. A phase II study of a novel anti-tubulin, E7389, in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 24 18S (2006) [abstr. 390]
66. Simmons T.L., Andrianasolo E., McPhail K., Flatt P., and Gerwick W.H. Marine natural products as anticancer drugs. Mol Cancer Ther 4 2 (2005) 333-342
67. Heath E.I., Alousi A., Eder J.P., et al. A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. Proc Am Soc Clin Oncol 24 18S (2006) [abstr. 85]
68. Perego P., De Cesare M., De Isabella P., Carenini N., Beggiolin G., Pezzoni G., et al. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61 16 (2001) 6034-6037
69. De Cesare M., Pratesi G., Perego P., Carenini N., Tinelli S., Merlini L., et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61 19 (2001) 7189-7195
70. Pratesi G., De Cesare M., Carenini N., Perego P., Righetti S.C., Cucco C., et al. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 8 12 (2002) 3904-3909
71. Pratesi G., Beretta G.L., and Zunino F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drug 15 6 (2004) 545-552
72. Mariani P., Moliterni A., Da Prada G., et al. Phase II trial of the novel oral camptothecin gimatecan (G) in women with anthracycline (A) and taxane (T) pre-treated advanced breast cancer. Proc Am Soc Clin Oncol 24 18S (2006) [abstr. 662]
73. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 6 7 (2006) 973-982
74. Petrylak D., Witjes F., Ferrero J., et al. Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results from a randomized phase III trial. J Clin Oncol 25 18S (2007) [abstr. 5019]
75. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7 8 (2007) 573-584
76. Rusthoven J.J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 17 4 (1999) 1194
77. Clarke S.J., Abratt R., Goedhals L., Boyer M.J., Millward M.J., and Ackland S.P. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13 5 (2002) 737-741
78. Smit E.F., Mattson K., von Pawel J., Manegold C., Clarke S., and Postmus P.E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14 3 (2003) 455-460
79. Bunn Jr. P.A. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol 29 3 Suppl. 9 (2002) 17-22
80. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 9 (2004) 1589-1597
81. Gronberg H., Bremnes R., Aasebo U., et al. Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer. J Clin Oncol 25 18S (2007) [abstr. 7517]
82. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 14 (2003) 2636-2644
83. Socinski M.A., Weissman C., Hart L.L., Beck J.T., Choksi J.K., Hanson J.P., et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24 30 (2006) 4840-4847
84. Smith I. Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. Oncology (Williston Park) 18 13 Suppl. 8 (2004) 63-65
85. Pivot X., Raymond E., Laguerre B., Degardin M., Cals L., Armand J.P., et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Brit J Cancer 85 5 (2001) 649-655
86. Bennouna J., Campone M., Delord J.P., and Pinel M.C. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drug 14 10 (2005) 1259-1267
87. Ngan V.K., Bellman K., Panda D., Hill B.T., Jordan M.A., and Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60 18 (2000) 5045-5051
88. Kruczynski A., and Hill B.T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 40 2 (2001) 159-173
89. Hill B.T., Fiebig H.H., Waud W.R., Poupon M.F., Colpaert F., and Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35 3 (1999) 512-520
90. Kruczynski A., Colpaert F., Tarayre J.P., Mouillard P., Fahy J., and Hill B.T. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41 6 (1998) 437-447
91. Barret J.M., Etievant C., and Hill B.T. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 45 6 (2000) 471-476
92. Bennouna J., Fumoleau P., Armand J.P., Raymond E., Campone M., Delgado F.M., et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14 4 (2003) 630-637
93. Campone M., Cortes-Funes H., Vorobiof D., Martin M., Slabber C.F., Ciruelos E., et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Brit J Cancer 95 9 (2006) 1161-1166
94. Bennouna J., Breton J.L., Tourani J.M., Ottensmeier C., O'Brien M., Kosmidis P., et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Brit J Cancer 94 10 (2006) 1383-1388
95. Zhou J., and Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5 1 (2005) 65-71